https://doi.org/10.4081/itjm.2024.1748
Expert consensus guideline on the diagnosis of type 1 Gaucher disease in adult patients
Published: 20 June 2024
Abstract Views: 95
PDF: 57
SUPPLEMENTARY MATERIAL: 23
SUPPLEMENTARY MATERIAL: 23
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Gaucher disease (GD) is a rare genetic disorder characterized by glucocerebrosidase deficiency. Over 50% of patients with mild disease go undiagnosed, suggesting that GD diagnosis rates are still significantly low despite advancements in medical knowledge and diagnostic techniques. This guideline explores the potential settings in which patients with mild to moderate GD may present, providing professional guidance on diagnostic avenues and highlighting the necessity of raising awareness among medical professionals. Patients with undiagnosed GD may be seen in departments such as neurology, transfusion medicine, centers for hepatic disorders, orthopedics, hemostasis, thrombosis, benign and general hematology, and reference centers for these conditions. Therefore, for a timely diagnosis and appropriate management of this rare disorder, it is crucial that these specialties collaborate effectively and devise a path that avoids needless and invasive procedures.
Pastores GM, Hughes DA. Gaucher Disease. GeneReviews®. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1269/ (accessed on October 8, 2023)
Alaei MR, Tabrizi A, Jafari N, Mozafari H. Gaucher disease: new expanded classification emphasizing neurological features. Iran J Child Neurol 2019;13:7-24.
Hughes D, Mikosch P, Belmatoug N, et al. Gaucher disease in bone: from pathophysiology to practice. J Bone Miner Res 2019;34:996-1013.
DOI: https://doi.org/10.1002/jbmr.3734
McCabe ERB, Fine BA, Golbus MS, et al. Gaucher Disease: Current Issues in Diagnosis and Treatment. JAMA 1996;275:548-53.
DOI: https://doi.org/10.1001/jama.275.7.548
Simon G, Erdos M, Maródi L, Tóth J. Gaucher disease: The importance of early diagnosis and therapy. Orv Hetil 2008;149(:743-50.
DOI: https://doi.org/10.1556/oh.2008.28337
Poupětová H, Ledvinová J, Berná L, et al. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 2010;33:387.
DOI: https://doi.org/10.1007/s10545-010-9093-7
Poorthuis BJHM, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6.
DOI: https://doi.org/10.1007/s004399900075
Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
DOI: https://doi.org/10.1001/jama.281.3.249
Mehta A, Belmatoug N, Bembi B, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab 2017;122:122-9.
DOI: https://doi.org/10.1016/j.ymgme.2017.08.002
Bouayadi O, Lyagoubi A, Aarab A, et al. Gaucher Disease: an underdiagnosed pathology in the eastern Moroccan population. EJIFCC 2019;30:82.
Pehrsson M, Heikkinen H, Wartiovaara-Kautto U, et al. Screening for potential undiagnosed Gaucher disease patients: Utilisation of the Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS) in conjunction with electronic health record data, tissue specimens, and small nucleotide polymorphism (SNP) genotype data available in Finnish biobanks. Mol Genet Metab Rep 2022;33.
DOI: https://doi.org/10.1016/j.ymgmr.2022.100911
Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004;163:58-66.
DOI: https://doi.org/10.1007/s00431-003-1362-0
Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: Recommendations for treatment and monitoring. Eur J Pediatr 2004;163:67-75.
Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004;163:67-75.
DOI: https://doi.org/10.1007/s00431-003-1363-z
Motta I, Consonni D, Stroppiano M, et al. Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Sci Rep 2021;11.
DOI: https://doi.org/10.1038/s41598-021-82296-z
Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis 2018;68:203-8.
DOI: https://doi.org/10.1016/j.bcmd.2016.10.008
Torralba-Cabeza MÁ, Olivera-González S, Sierra-Monzón JL. The importance of a multidisciplinary approach in the management of a patient with type I Gaucher disease. Diseases 2018;6:69.
DOI: https://doi.org/10.3390/diseases6030069
Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004;144:112-20.
DOI: https://doi.org/10.1016/j.jpeds.2003.10.067
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95.
DOI: https://doi.org/10.1016/j.jbi.2019.103208
Marchi G, Nascimbeni F, Motta I, et al. Hyperferritinemia and diagnosis of type 1 Gaucher disease. Am J Hematol 2020;95:570-6.
DOI: https://doi.org/10.1002/ajh.25752
Mehta A, J Kuter DJ, Salek SS, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. Intern Med J 2019;49:578-91.
DOI: https://doi.org/10.1111/imj.14156
Costello R, O’Callaghan T, Sébahoun G. Gaucher disease and multiple myeloma. Leuk Lymphoma 2006;47:1365-8.
DOI: https://doi.org/10.1080/10428190600565453
Mistry PK, Cappellini MD, et al. Consensus Conference: a reappraisal of Gaucher disease - diagnosis and disease management algorithms. Am J Hematol 2011;86:110.
DOI: https://doi.org/10.1002/ajh.21888
Linari S, Castaman G. Hemostatic abnormalities in Gaucher disease: mechanisms and clinical implications. J Clin Med 2022;11:6920.
DOI: https://doi.org/10.3390/jcm11236920
Barone R, Giuffrida G, Musso R, et al. Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I. J Inherit Metab Dis 2000;23:387-90.
DOI: https://doi.org/10.1023/A:1005655903139
Mitrovic M, Antic D, Elezovic I, et al. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher’s disease. Platelets 2012;23:143-9.
DOI: https://doi.org/10.3109/09537104.2011.597526
Komninaka V, Repa K, Marinakis T, et al. Platelet function defects in patients with Gaucher disease on long term ERT- implications for evaluation at bleeding challenges. Blood Cells Mol Dis 2020;80.
DOI: https://doi.org/10.1016/j.bcmd.2019.102371
Serratrice C, Cherin P, Lidove O, et al. Coagulation Parameters in adult patients with type-1 Gaucher disease. J Hematol 2019;8:121.
DOI: https://doi.org/10.14740/jh543
Boklan BF, Sawitsky A. Factor IX deficiency in Gaucher disease: an in vitro phenomenon. Arch Intern Med 1976;136:489-92.
DOI: https://doi.org/10.1001/archinte.136.4.489
How to Cite
De Vivo, A., Marconi, G., Tumedei, N., Luicchini, E., Finazzi, M. C., Burgo, I. M., Forni, G. L., & Linari, S. (2024). Expert consensus guideline on the diagnosis of type 1 Gaucher disease in adult patients. Italian Journal of Medicine, 18(2). https://doi.org/10.4081/itjm.2024.1748
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
